The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects
Abstract Interleukin-17A (IL-17A) plays a pivotal role in many rheumatic immune-mediated inflammatory diseases. Targeting the IL-17 pathway has transformed the way psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are managed, with a number of IL-17A inhibitors now available for treating...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-025-00754-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309892711546880 |
|---|---|
| author | Sofia Ramiro Georg Schett Helena Marzo-Ortega Wolfgang A. Schmidt |
| author_facet | Sofia Ramiro Georg Schett Helena Marzo-Ortega Wolfgang A. Schmidt |
| author_sort | Sofia Ramiro |
| collection | DOAJ |
| description | Abstract Interleukin-17A (IL-17A) plays a pivotal role in many rheumatic immune-mediated inflammatory diseases. Targeting the IL-17 pathway has transformed the way psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are managed, with a number of IL-17A inhibitors now available for treating rheumatic and musculoskeletal diseases. This narrative review will describe the opportunities presented by novel imaging techniques in understanding the metabolic and mechanical changes that characterize the pathogenesis of PsA and axSpA. It will look at the current consensus definitions of early disease in PsA and axSpA, present evidence for the benefit of early treatment, and highlight the gaps in current knowledge. Finally, it will describe novel treatment targets to address the unmet needs in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) and discuss the potential role of IL-17A inhibition in treating GCA and PMR. |
| format | Article |
| id | doaj-art-489a977945f54a7ca62b27345fe8598c |
| institution | Kabale University |
| issn | 2198-6576 2198-6584 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj-art-489a977945f54a7ca62b27345fe8598c2025-08-20T03:53:57ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842025-04-0112343545110.1007/s40744-025-00754-wThe Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future ProspectsSofia Ramiro0Georg Schett1Helena Marzo-Ortega2Wolfgang A. Schmidt3Leiden University Medical Center, Leiden and Zuyderland Medical CenterDepartment of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum ErlangenNIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospital NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of LeedsImmanuel Krankenhaus BerlinAbstract Interleukin-17A (IL-17A) plays a pivotal role in many rheumatic immune-mediated inflammatory diseases. Targeting the IL-17 pathway has transformed the way psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are managed, with a number of IL-17A inhibitors now available for treating rheumatic and musculoskeletal diseases. This narrative review will describe the opportunities presented by novel imaging techniques in understanding the metabolic and mechanical changes that characterize the pathogenesis of PsA and axSpA. It will look at the current consensus definitions of early disease in PsA and axSpA, present evidence for the benefit of early treatment, and highlight the gaps in current knowledge. Finally, it will describe novel treatment targets to address the unmet needs in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) and discuss the potential role of IL-17A inhibition in treating GCA and PMR.https://doi.org/10.1007/s40744-025-00754-wAxial spondyloarthritisEarly treatmentEarly diagnosisGiant cell arteritisIL-17AIL-17A inhibition |
| spellingShingle | Sofia Ramiro Georg Schett Helena Marzo-Ortega Wolfgang A. Schmidt The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects Rheumatology and Therapy Axial spondyloarthritis Early treatment Early diagnosis Giant cell arteritis IL-17A IL-17A inhibition |
| title | The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects |
| title_full | The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects |
| title_fullStr | The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects |
| title_full_unstemmed | The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects |
| title_short | The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects |
| title_sort | impact of il 17a inhibition in rheumatic and musculoskeletal diseases current insights and future prospects |
| topic | Axial spondyloarthritis Early treatment Early diagnosis Giant cell arteritis IL-17A IL-17A inhibition |
| url | https://doi.org/10.1007/s40744-025-00754-w |
| work_keys_str_mv | AT sofiaramiro theimpactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT georgschett theimpactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT helenamarzoortega theimpactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT wolfgangaschmidt theimpactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT sofiaramiro impactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT georgschett impactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT helenamarzoortega impactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects AT wolfgangaschmidt impactofil17ainhibitioninrheumaticandmusculoskeletaldiseasescurrentinsightsandfutureprospects |